Manufacturing technology of Contraflu involves two major steps:


1) Patent-protected step:

- manufacturing of starting active substance – purified rabbit polyclonal immune antibodies, with an original technology;

2) Generic step:

- manufacturing of finished dosage form (oral tablets), with generic technology covered by the Pharmacopoeia.




- Fully GMP compliant technology;

- Can be easily up-scaled;

- Low manufacturing cost (< $.70 for a USA-based manufacturer);

- Substance manufacturing technology is transferable to another facility.

Note for partners:

Manufacturing know-how is a part of Cont®aFlu IP package offered for acquisition. 

It will be disclosed as a step of due diligence before entering into the Licensing Agreement. 

Press here for details of our IP acquisition proposal.

© 2015-2019 by Cont®aFlu. All Rights Reserved.